Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the following investor conference.

Event: The Canaccord Genuity 44th Annual Growth Conference Date: Tuesday, August 13, 2024 Time: 12:30 – 12:55 PM ET

The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days following the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730687924/en/

Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: [phone] Email: [e-mail]

Media: Email: [e-mail]